Calton & Associates Inc. Has $751,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Calton & Associates Inc. increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 137.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,634 shares of the biopharmaceutical company's stock after purchasing an additional 17,151 shares during the period. Calton & Associates Inc.'s holdings in Pfizer were worth $751,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. bought a new position in Pfizer in the first quarter valued at $28,000. Bernard Wealth Management Corp. bought a new position in shares of Pfizer in the 4th quarter valued at about $30,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer in the 1st quarter valued at about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.8%

Shares of NYSE:PFE traded down $0.21 during trading on Monday, reaching $24.27. 33,436,955 shares of the stock traded hands, compared to its average volume of 41,925,861. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a 50-day moving average of $24.07 and a two-hundred day moving average of $24.71. The stock has a market cap of $137.96 billion, a P/E ratio of 17.58, a price-to-earnings-growth ratio of 0.89 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.82 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.09%. Pfizer's dividend payout ratio is currently 124.64%.

Analysts Set New Price Targets

PFE has been the topic of a number of research reports. Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Redburn Atlantic decreased their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. BMO Capital Markets decreased their price objective on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Finally, Wolfe Research increased their price target on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.